NCI, NCRI and EORTC working group outline risk-assessment approach for biomarker-driven cancer clinical trials
29 Apr 2014
In an article published in The Lancet Oncology, an NCI (US National Cancer Institute), NCRI (UK National Cancer Research Institute), and EORTC (European Organisation for Research and Treatment of Cancer) working group outline a practical risk-management approach for effective integration of biomarkers into cancer clinical trials. Their work provides the international community with a set of common principles by which biomarkers can be integrated into clinical trials, exchange of data can be facilitated, quality promoted, and research accelerated while simultaneously respecting local approaches and legislation.
Their risk-assessment approach for designing and conducting cancer clinical trials include risks to patient safety, operational risks, and biomarker development risks, and for each risk they evaluate possible consequences, provide solutions along with examples of these as well as references to helpful resources. Concerning protocol design, the working group recommends items that a protocol should include as well as items that should be assessed during protocol development. For the conduct of the trial, they make recommendations for the close monitoring of variability in test results, and they also make recommendations for particular aspects following completion of the trial.
Dr. Jacqueline Hall, who coordinated this NCI, NCRI, and EORTC working group says, “We readily acknowledge that in today’s clinical trial landscape, many stakeholders play a role in clinical trials. These include regulators, public authorities, and patients, amongst others. By opening this discussion to others, we hope to find solutions to the varied challenges facing molecularly driven clinical research.”
Support for this research came from the EORTC Charitable Trust and the UK Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme.
For more information please contact: www.eortc.org/contact
John Bean, PhD
EORTC, Medical Science Writer
Related News
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Interview of ROSC Chair, Joost Vaerhoeff
28 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group
24 Apr 2026
Investing in the future of cancer research; EORTC’s Young and Early Career investigator Network shows its value
23 Apr 2026
In Memoriam of Martine Van Glabbeke (1951-2026)
17 Apr 2026
PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases
27 Feb 2026
EORTC celebrates Rare Disease Day: Addressing unmet needs in rare cancers
27 Feb 2026
First Site Activated in EORTC RENALUT Clinical Trial on Metastatic Clear Cell Renal Cell Carcinoma
26 Feb 2026
